The combination therapy of pemetrexed and continued EGFR-TKIs beyond disease progression to first-line EGFR-TKIs treatments in elderly patients with advanced non-small-cell lung cancer harboring EGFR mutations: a phase 2 trial.
Not Applicable
Completed
- Conditions
- non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000010935
- Lead Sponsor
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria are as follows 1: Symptomatic brain metastasis. 2: History of radiotherapy to primary lesion. 3: Severe and unstable medical comorbidities. 4: Difficulty in ingestion. 5: With third-space fluid to be drained. 6: Pregnant or breastfeeding women. Willing to get pregnant. 7: Contraindication for taking EGFR-TKIs. 8: Active double cancers. 9: History of severe allergy to drugs. 10: Judgment to attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease control rate
- Secondary Outcome Measures
Name Time Method Progression free survival, overall survival, adverse events